Join for findings from new research!
If you are having trouble reading this email, read the online version | | August
24
2:00PM ET / 11:00am PT |
| | Discovering the absorption profile of a phospholipid-enhanced fish oil |
|---|
|
| |
|
|
| | Adequate consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with favorable health outcomes, but 90% of U.S. adults do not meet the recommended intake. Supplementation of EPA and DHA is a promising avenue for mitigating this shortfall. Not surprisingly, the market is constantly looking for ways to boost EPA and DHA absorption.
A new study published in the journal Nutrition assessed the bioavailability of EPA and DHA in a phospholipid-enhanced fish oil (PEFO) product compared to a traditional krill oil (KO) product in healthy adults.
Join us on August 24 for a discussion with Kevin C. Maki, Ph.D., founder and chief scientist for Midwest Biomedical Research, on the recent results of the study. We’ll dig into the findings and discuss the questions they raise.
|
Karen Raterman
Associate Director, Natural Products Insider | | Kevin C. Maki, Ph.D
Founder & Chief Scientist, Midwest Biomedical Research | |
|---|
|
Liana L. Guarneiri, Ph.D
Clinical Scientist, Midwest Biomedical Research
|
|---|
|
| |
|
This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy).
Informa PLC's registered office is 5 Howick Place, London SW1P 1WG.
Registered in England and Wales. Number 8860726.
If you do not wish to receive further information from us, please click here.
Alternatively, to contact our data services team to have your details or preferences updated please email [email protected]. 